Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly posts 151–164

I had written a reply contradicting post #148 and deleted it. Here is what survived.

The honest answer on tirzepatide in type 2 diabetes is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.

Most people get the first two right and then argue about the fourth.

The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.

Worth reading the earlier posts in this thread before acting on mine.

Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.

Adding the measurement that post #151 says would settle it.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

Reporting rather than recommending, on tirzepatide in type 2 diabetes. What happened is above. Whether it should have is a different question and not one I am qualified to answer.

Fine by me. I had wanted a stronger conclusion and there is not one available.

On post #155 — agreed on the reasoning, with one qualification.

Checked the tirzepatide in type 2 diabetes claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.

Picking up post #155: that is the part I would want checked first.

SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed diabetes dose at the time and it was not the highest dose available in the class, so the trial answers a narrower question than the headline implies.

The answer changed when I changed how I was measuring, which was informative.

Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you would expect from a between-person difference rather than a between-drug one.

Post #159 answers the question as asked. The question underneath it is different.

On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.

That is clearer than the version I had in my head. Thank you.

The titration schedule has more steps than semaglutide's, which reflects the finer gradation used in the clinical programme rather than a pharmacological requirement for smaller steps.

Where I would push back on the tirzepatide in type 2 diabetes consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Written quickly, so the reasoning may be tighter than the wording.